Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €278.05 EUR
Change Today +1.70 / 0.62%
Volume 19.3K
As of 11:39 AM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

sartorius stedim biotech (DIM) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/21/15 - €294.10
52 Week Low
10/16/14 - €120.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sartorius stedim biotech (DIM) Related Businessweek News

No Related Businessweek News Found

sartorius stedim biotech (DIM) Details

Sartorius Stedim Biotech S.A. provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry worldwide. The company’s integrated solutions cover fermentation, filtration, purification, fluid management, and lab technologies that support the biopharmaceutical industry to develop and produce drugs. It provides various products, such as media for cell cultivation; bioreactors in various sizes for cell propagation; filters for purifying cell materials; systems for storage and transportation of finished products; and single-use bags for fermentation applications. The company also offers validation and consulting services, as well as equipment installation, maintenance, and repair services. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. Sartorius Stedim Biotech S.A. was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

3,925 Employees
Last Reported Date: 07/21/15
Founded in 1870

sartorius stedim biotech (DIM) Top Compensated Officers

Chairman of The Board and Chief Executive Off...
Total Annual Compensation: €1.0M
Executive Vice President of Operations & IT a...
Total Annual Compensation: €543.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: €543.0K
Executive Vice President of Marketing Sales &...
Total Annual Compensation: €636.0K
Compensation as of Fiscal Year 2014.

sartorius stedim biotech (DIM) Key Developments

Sartorius Stedim Biotech and GE Healthcare Sign Worldwide OEM Supply Agreement

Sartorius Stedim Biotech SA and GE Healthcare's Life Sciences business have entered into a worldwide original equipment manufacturer, or OEM, supply agreement for SSB's membrane adsorber purification technology, Sartobind. Under the terms of the agreement, SSB will manufacture membrane adsorber technologies for GE which will be marketed as part of GE's ReadyToProcess product offerings. Membrane adsorber ion-exchange technology is widely used in the industry for the removal of contaminants such as endotoxins and viruses during the production of protein-based drugs, and can offer manufacturers advantages compared to other techniques. The new products will be marketed by GE under the brand 'ReadyToProcess Adsorber'.

Sartorius Stedim Biotech S.A. Reports Earnings Results for the First Half of 2015; Provides Earnings Guidance for the Full Year of 2015

Sartorius Stedim Biotech S.A. reported earnings results for the first half of 2015. For the first half, the company reported sales revenue of EUR 422.0 million compared to EUR 324.1 million a year ago. EBITDA was EUR 106.5 million compared to EUR 73.8 million a year ago. Net profit was EUR 62.9 million or EUR 4.10 per share compared to EUR 40.7 million or EUR 2.65 per share a year ago. Net debt at the end of the first half year was EUR 111.3 million. Underlying EBITDA rose 44.3% to EUR 106.5 million. Underlying earnings per share were EUR 4.10, up year over year from EUR 2.65. Based on the strong results of the first six months and the two recent acquisitions, management has upgraded its forecast for the full year of 2015. Sales revenue in constant currencies is now expected to increase approx. 15%, which includes approx. 1.5 percentage points from the acquisitions of BioOutsource and Cellca. The underlying EBITDA margin in constant currencies is forecasted to reach around 25.0% to 25.5%.

Sartorius Stedim Biotech S.A. Presents at 12th Annual Goldman Sachs European Medtech and Healthcare Services Conference, Sep-09-2015

Sartorius Stedim Biotech S.A. Presents at 12th Annual Goldman Sachs European Medtech and Healthcare Services Conference, Sep-09-2015 . Venue: London, United Kingdom.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DIM:FP €278.05 EUR +1.70

DIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Corning Inc $17.81 USD +0.17
General Electric Co $27.29 USD +0.47
Thermo Fisher Scientific Inc $124.09 USD -2.46
View Industry Companies

Industry Analysis


Industry Average

Valuation DIM Industry Range
Price/Earnings 47.9x
Price/Sales 5.5x
Price/Book 7.3x
Price/Cash Flow 47.9x
TEV/Sales 5.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SARTORIUS STEDIM BIOTECH, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at